Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025)

Artiva Biotherapeutics (ARTV) reported Capital Leases of $11000.0 for Q1 2025, down 75.0% quarter-over-quarter from $44000.0 in Q4 2024.

Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of Capital Leases data on file, last reported at $11000.0 in Q1 2025.

Capital Leases for Q1 2025 came in at $11000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $11000.0 (changed N/A YoY), and the FY2024 annual result was $44000.0, changed N/A from the prior year.
Capital Leases retreated to $11000.0 in Q1 2025 per ARTV's latest filing, from $44000.0 in the prior quarter.
Over five years, Capital Leases peaked at $106000.0 in Q2 2024 and troughed at $11000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Artiva Biotherapeutics	241.85 Mn	241.85 Mn	-

Download Data